Gemcitabine based combination chemotherapy, a new salvage regimen for recurrent platinum resistant epithelial ovarian cancer
10.3760/cma.j.issn.0529-567x.2010.11.003
- VernacularTitle:以吉西他滨为基础的联合化疗治疗复发性铂类耐药卵巢上皮性癌的临床观察
- Author:
Ping CHU
;
Chunhua LU
;
Xiugui SHENG
;
Caixia ZHOU
;
Dapeng LI
;
Xuelian DU
;
Naifu LIU
- Publication Type:Journal Article
- Keywords:
Antineoplastic combined chemotherapy protocols;
Ifosfamide;
Ovarian neoplasms;
Neoplasm recurrence,local;
Gemcitabine
- From:
Chinese Journal of Obstetrics and Gynecology
2010;45(11):808-812
- CountryChina
- Language:Chinese
-
Abstract:
Objective To evaluate the efficacy and toxicities of gemcitabine combined with ifosfamide and anthracycline chemotherapy for recurrent platinum resistant ovarian epithelial cancer.Methods Gemcitabine 800 mg/m2 ( day 1, 8 ), ifosfamide 1.5 g/m2 ( day 1 - 3 ), adriamycin 40 mg/m2 or epirubicin 60 mg/m2 (day 1 ) or mitoxantrone 10 mg/m2 (day 1, 8 ) were used in recurrent platinum resistant/refractory ovarian cancer patients, the cycle was repeated at interval of 21 to 28 days.Results A total of 60 patients received 172 cycles combined chemotherapy.There were no one cases complete response, while partial response 22 (37%, 22/60), stable 23 (38%, 23/60) and progression 15 (25%,15/60) were observed, with clinical benefit rate 75% (45/60).The median time of progression-free survival was 7 months, and the median overall survival time was 20 months.The main side effect was hematologic toxicity with leukopenia rate of 82% (49/60), among which Ⅲ - Ⅳ accounted for 31%(15/49).Digestive reaction was all in Ⅰ - Ⅱ , accounted for 42% (25/60).Conclusion The regimen of gemcitabine combined with ifosfamide and anthracycline is feasible, tolerable and effective in patients with recurrent platinum resistant/refractory epithelial ovarian cancer.
